Asunto(s)
Meningitis Fúngica/economía , Meningitis Fúngica/microbiología , Candida albicans/genética , Candida albicans/aislamiento & purificación , Candida albicans/fisiología , Candidiasis/diagnóstico , Candidiasis/economía , Candidiasis/microbiología , Candidiasis/mortalidad , Costo de Enfermedad , Criptococosis/diagnóstico , Criptococosis/economía , Criptococosis/microbiología , Criptococosis/mortalidad , Cryptococcus neoformans/genética , Cryptococcus neoformans/aislamiento & purificación , Cryptococcus neoformans/fisiología , Humanos , Meningitis Fúngica/diagnóstico , Meningitis Fúngica/mortalidadRESUMEN
OBJECTIVES: We assessed the economic burden of AIDS-defining illnesses (ADIs), which was further stratified by adherence to antiretroviral therapy (ART). METHODS AND MATERIALS: A nationwide longitudinal cohort of 18,234 incident cases with HIV followed for 11years was utilized. Adherence to ART was measured by medication possession ratio (MPR). Generalized estimating equations modeling was used to estimate the cost impact of ADIs. RESULTS: Having opportunistic infections increased the annual cost by 9% (varicella-zoster virus infection) to 98% (cytomegalovirus disease), while the annual costs increased by 26% (Kaposi's sarcoma) to 95% (non-Hodgkin's lymphoma) in the year when AIDS-related cancer occurred. ADIs occurred more frequently in the years with low adherence for ART compared to the high-adherence years (e.g., 0.1≤MPR<0.8 vs. MPR≥0.8, event rate of cytomegalovirus disease 4.03% vs. 0.51%). The annual baseline costs in the years with MPR<0.1, 0.1≤MPR<0.8, and MPR≥0.8 were $250, $4,752, and $8,990 (in 2018 USD), respectively. The economic impact of ADIs in the years with low adherence (MPR<0.1) was larger than that in the high-adherence years (MPR≥0.8) (e.g., MPR<0.1 vs. MPR≥0.8, annual cost increased by 244% vs. 9% when candidiasis occurred). CONCLUSIONS: Adherence to ART may increase the baseline medical costs but mitigate the incidence and economic burden of ADIs.
Asunto(s)
Infecciones Oportunistas Relacionadas con el SIDA/economía , Síndrome de Inmunodeficiencia Adquirida/tratamiento farmacológico , Fármacos Anti-VIH/economía , Adulto , Fármacos Anti-VIH/uso terapéutico , Candidiasis/complicaciones , Candidiasis/economía , Costo de Enfermedad , Infecciones por Citomegalovirus/complicaciones , Infecciones por Citomegalovirus/economía , Femenino , Humanos , Estudios Longitudinales , Linfoma no Hodgkin/complicaciones , Linfoma no Hodgkin/economía , Masculino , Persona de Mediana Edad , Sarcoma de Kaposi/complicaciones , Sarcoma de Kaposi/economía , Infección por el Virus de la Varicela-Zóster/complicaciones , Infección por el Virus de la Varicela-Zóster/economíaRESUMEN
PURPOSE: Previous epidemiological and cost studies of fungal meningitis have largely focused on single pathogens, leading to a poor understanding of the disease in general. We studied the largest and most diverse group of fungal meningitis patients to date, over the longest follow-up period, to examine the broad impact on resource utilization within the United States. METHODOLOGY: The Truven Health Analytics MarketScan database was used to identify patients with a fungal meningitis diagnosis in the United States between 2000 and 2012. Patients with a primary diagnosis of cryptococcal, Coccidioides, Histoplasma, or Candida meningitis were included in the analysis. Data concerning healthcare resource utilization, prevalence and length of stay were collected for up to 5 years following the original diagnosis. RESULTS: Cryptococcal meningitis was the most prevalent type of fungal meningitis (70.1â% of cases over the duration of the study), followed by coccidioidomycosis (16.4â%), histoplasmosis (6.0â%) and candidiasis (7.6â%). Cryptococcal meningitis and candidiasis patients accrued the largest average charges ($103â236 and $103â803, respectively) and spent the most time in the hospital on average (70.6 and 79 days). Coccidioidomycosis and histoplasmosis patients also accrued substantial charges and time in the hospital ($82â439, 48.1 days; $78â609, 49.8 days, respectively). CONCLUSION: Our study characterizes the largest longitudinal cohort of fungal meningitis in the United States. Importantly, the health economic impact and long-term morbidity from these infections are quantified and reviewed. The healthcare resource utilization of fungal meningitis patients in the United States is substantial.
Asunto(s)
Costo de Enfermedad , Recursos en Salud/estadística & datos numéricos , Meningitis Fúngica/epidemiología , Meningitis Fúngica/microbiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Candidiasis/economía , Candidiasis/epidemiología , Candidiasis/microbiología , Coccidioidomicosis/economía , Coccidioidomicosis/epidemiología , Coccidioidomicosis/microbiología , Femenino , Histoplasmosis/economía , Histoplasmosis/epidemiología , Histoplasmosis/microbiología , Humanos , Masculino , Meningitis Criptocócica/economía , Meningitis Criptocócica/epidemiología , Meningitis Criptocócica/microbiología , Meningitis Fúngica/diagnóstico , Meningitis Fúngica/economía , Persona de Mediana Edad , Prevalencia , Estados Unidos/epidemiología , Adulto JovenRESUMEN
Objective Outcomes for gastroschisis (GS) remain highly variable and avoiding infectious complications (ICs) may represent a significant improvement opportunity. Our objective was to provide estimates of the impact of IC on length of stay (LOS) and costs. Study Design Using a national database, 1,378 patients with GS were identified. Patient and hospital characteristics were compared and LOS and costs evaluated for patients with and without IC. Results Two-thirds of all GS patients had IC, and IC were common for simple and complex GS (65, 73%, respectively). After controlling for patient and hospital factors, LOS in patients with IC was significantly longer than in patients without IC (4.5-day increase, p = 0.001). Specifically, sepsis was associated with increasing median LOS by 11 days (p ≤ 0.001), candida infection by 14 days (p < 0.001), and wound infection by 7 days (p = 0.007). Although overall costs did not differ between patients with and without IC, costs were elevated based on specific IC. Sepsis increased median costs by $22,380 (95% confidence interval [CI]: $14,372-30,388; p ≤ 0.001), wound infection by $32,351 (95% CI: $17,221-47,481; p ≤ 0.001), catheter-related infection by $57,180 (95% CI: $12,834-101,527; p = 0.011), and candida infections by $24,500 (95% CI: $8,832-40,167; p = 0.002). Conclusion IC among GS patients are common and contribute to increased LOS and costs. Quantifying clinical and financial ramifications of IC may help direct future quality improvement efforts.
Asunto(s)
Candidiasis/epidemiología , Gastrosquisis/cirugía , Costos de la Atención en Salud , Tiempo de Internación/estadística & datos numéricos , Sepsis/epidemiología , Infección de la Herida Quirúrgica/epidemiología , Candidiasis/economía , Bases de Datos Factuales , Femenino , Costos de Hospital , Humanos , Recién Nacido , Cuidado Intensivo Neonatal/economía , Tiempo de Internación/economía , Masculino , Complicaciones Posoperatorias/economía , Complicaciones Posoperatorias/epidemiología , Estudios Retrospectivos , Sepsis/economía , Infección de la Herida Quirúrgica/economíaRESUMEN
PURPOSE: Evidence shows that single-patient rooms can play an important role in preventing cross-transmission and reducing nosocomial infections in intensive care units (ICUs). This case study investigated whether cost savings from reductions in nosocomial infections justify the additional construction and operation costs of single-bed rooms in ICUs. MATERIALS AND METHODS: We conducted deterministic and probabilistic return-on-investment analyses of converting the space occupied by open-bay rooms to single-bed rooms in an exemplary ICU. We used the findings of a study of an actual ICU in which the association between the locations of patients in single-bed vs open-bay rooms with infection risk was evaluated. RESULTS: Despite uncertainty in the estimates of costs, infection risks, and length of stay, the cost savings from the reduction of nosocomial infections in single-bed rooms in this case substantially outweighed additional construction and operation expenses. The mean value of internal rate of return over a 5-year analysis period was 56.18% (95% credible interval, 55.34%-57.02%). CONCLUSIONS: This case study shows that although single-patient rooms are more costly to build and operate, they can result in substantial savings compared with open-bay rooms by avoiding costs associated with nosocomial infections.
Asunto(s)
Ahorro de Costo/economía , Infección Hospitalaria/economía , Unidades de Cuidados Intensivos/economía , Modelos Económicos , Habitaciones de Pacientes/economía , Canadá , Candidiasis/economía , Candidiasis/prevención & control , Infección Hospitalaria/prevención & control , Costos de Hospital , Arquitectura y Construcción de Hospitales/economía , Humanos , Staphylococcus aureus Resistente a Meticilina , Infecciones por Pseudomonas/economía , Infecciones por Pseudomonas/prevención & control , Infecciones Estafilocócicas/economía , Infecciones Estafilocócicas/prevención & controlRESUMEN
Invasive fungal diseases (IFDs) have been widely studied in recent years, largely because of the increasing population at risk. Aspergillus and Candida species remain the most common causes of IFDs, but other fungi are emerging. The early and accurate diagnosis of IFD is critical to outcome and the optimisation of treatment. Rapid diagnostic methods and new antifungal therapies have advanced disease management in recent years. Strategies for the prevention and treatment of IFDs include prophylaxis, and empirical and pre-emptive therapy. Here, we review the available primary literature on the clinical and economic burden of IFDs in Europe from 2000 to early 2011, with a focus on the value and outcomes of different approaches.
Asunto(s)
Aspergilosis/economía , Aspergilosis/epidemiología , Candidiasis/economía , Candidiasis/epidemiología , Antifúngicos/uso terapéutico , Aspergilosis/diagnóstico , Aspergilosis/tratamiento farmacológico , Candidiasis/diagnóstico , Candidiasis/tratamiento farmacológico , Técnicas de Laboratorio Clínico/métodos , Diagnóstico Precoz , Europa (Continente)/epidemiología , HumanosRESUMEN
BACKGROUND: Systemic Candida infections (SCI) occur predominantly in intensive care unit patients and are a common cause of morbidity and mortality. Recently, changes in Candida epidemiology with an increasing prevalence of SCI caused by Candida non-albicans species have been reported. Resistance to fluconazole and azoles in general is not uncommon for non-albicans species. Despite guidelines recommending initial treatment with broad-spectrum antifungals such as echinocandins with subsequent switch to fluconazole if isolates are sensitive (de-escalation strategy), fluconazole is still the preferred first-line antifungal (escalation) in many clinical practice settings. After diagnosis of the pathogen, the initial therapy with fluconazole is switched to a broad-spectrum antifungal if a non-albicans is identified. METHODS: The cost-effectiveness of initial treatment with micafungin (de-escalation) vs fluconazole (escalation) in patients with SCI was estimated using decision analysis based on clinical and microbiological data from pertinent studies. The model horizon was 42 days, and was extrapolated to cover a lifetime horizon. All costs were analyzed from the UK NHS perspective. Several assumptions were taken to address uncertainties; the limitations of these assumptions are discussed in the article. RESULTS: In patients with fluconazole-resistant isolates, initial treatment with micafungin avoids 30% more deaths and successfully treats 23% more patients than initial treatment with fluconazole, with cost savings of £1621 per treated patient. In the overall SCI population, de-escalation results in 1.2% fewer deaths at a marginal cost of £740 per patient. Over a lifetime horizon, the incremental cost-effectiveness of de-escalation vs escalation was £15,522 per life-year and £25,673 per QALY. CONCLUSIONS: De-escalation from micafungin may improve clinical outcomes and overall survival, particularly among patients with fluconazole-resistant Candida strains. De-escalation from initial treatment with micafungin is a cost-effective alternative to escalation from a UK NHS perspective, with a differential cost per QALY below the 'willingness-to-pay' threshold of £30,000.
Asunto(s)
Antifúngicos/economía , Antifúngicos/uso terapéutico , Candidiasis/tratamiento farmacológico , Equinocandinas/economía , Equinocandinas/uso terapéutico , Lipopéptidos/economía , Lipopéptidos/uso terapéutico , Antifúngicos/administración & dosificación , Candidiasis/economía , Candidiasis/mortalidad , Análisis Costo-Beneficio , Técnicas de Apoyo para la Decisión , Equinocandinas/administración & dosificación , Fluconazol/economía , Fluconazol/uso terapéutico , Servicios de Salud/economía , Servicios de Salud/estadística & datos numéricos , Humanos , Esperanza de Vida , Lipopéptidos/administración & dosificación , Micafungina , Pruebas de Sensibilidad Microbiana , Años de Vida Ajustados por Calidad de VidaRESUMEN
The echinocandins are antifungal agents, which act by inhibiting the synthesis of ß-(1,3)-D-glucan, an integral component of fungal cell walls. Caspofungin, the first approved echinocandin, demonstrates good in vitro and in vivo activity against a range of Candida species and is an alternative therapy for Aspergillus infections. Caspofungin provides an excellent safety profile and is therefore favoured in patients with moderately severe to severe illness, recent azole exposure and in those who are at high risk of infections due to Candida glabrata or Candida krusei. In vivo/in vitro resistance to caspofungin and breakthrough infections in patients receiving this agent have been reported for Candida and Aspergillus species. The types of pathogens and the frequency causing breakthrough mycoses are not well delineated. Caspofungin resistance resulting in clinical failure has been linked to mutations in the Fksp subunit of glucan synthase complex. European Committee for Antimicrobial Susceptibility Testing and Clinical and Laboratory Standards Institute need to improve the in vitro susceptibility testing methods to detect fks hot spot mutants. Caspofungin represents a significant advance in the care of patients with serious fungal infections.
Asunto(s)
Aspergillus/efectos de los fármacos , Biopelículas , Candida/efectos de los fármacos , Equinocandinas/uso terapéutico , Antifúngicos/metabolismo , Antifúngicos/farmacocinética , Antifúngicos/uso terapéutico , Aspergilosis/tratamiento farmacológico , Aspergilosis/economía , Aspergilosis/microbiología , Aspergillus/metabolismo , Aspergillus/fisiología , Candida/metabolismo , Candida/fisiología , Candidiasis/tratamiento farmacológico , Candidiasis/economía , Candidiasis/microbiología , Caspofungina , Pared Celular/efectos de los fármacos , Pared Celular/metabolismo , Ensayos Clínicos como Asunto , Farmacorresistencia Fúngica , Equinocandinas/metabolismo , Equinocandinas/farmacocinética , Glucosiltransferasas/metabolismo , Guías como Asunto , Humanos , Lipopéptidos , Proteoglicanos , beta-Glucanos/metabolismoRESUMEN
OBJECTIVE: To estimate the cost of 3 candins (anidulafungin, caspofungin and micafungin) in the treatment of adult non-neutropaenic patients with invasive candidiasis (IC) in a Spanish hospital pharmacy setting. METHODS: The overall cost impact was evaluated by varying the percentage dosage required of each candin in different possible scenarios. The prices (in euros) for each presentation were obtained from the Drug Catalogue (in August 2010). Only drug purchase costs were considered. The results are expressed as total cost for each of the 3 candins. RESULTS: The cost per episode (14 days) of anidulafungin was constant at 5400 per patient. The cost of caspofungin varied from 4281 to 7991, depending on patient weight and liver dysfunction. The cost of micafungin varied from 6000 (100mg/day) to 9000 (when increasing the dose due to inadequate response). Based on a hypothetic cohort of 100 patients with IC, the total cost of anidulafungin treatment would be 540,000, for caspofungin it would be 631,459, and for micafungin it would be 632,998, depending on any dose adjustment required. CONCLUSION: Patients treated with anidulafungin did not require dose adjustment, unlike those treated with caspofungin or micafungin. The use of anidulafungin is a cost-saving treatment for adult non-neutropaenic patients with IC, which would result in better control of the Spanish pharmacy budget.
Asunto(s)
Antifúngicos/economía , Antifúngicos/uso terapéutico , Candidiasis/tratamiento farmacológico , Candidiasis/economía , Equinocandinas/economía , Equinocandinas/uso terapéutico , Lipopéptidos/economía , Lipopéptidos/uso terapéutico , Adulto , Anidulafungina , Antifúngicos/administración & dosificación , Caspofungina , Costos y Análisis de Costo , Costos de los Medicamentos , Equinocandinas/administración & dosificación , Humanos , Lipopéptidos/administración & dosificación , Micafungina , Servicio de Farmacia en Hospital/economía , EspañaRESUMEN
BACKGROUND: Data on Candida infection among critically ill trauma patients are limited and not recently updated. Here we study the epidemiology and economic impact of Candida and examine potential risk factors for Candida infection in this population. METHODS: In this 5-year retrospective study, all severely injured patients with ≥4 days of intensive care unit stay were included, with the primary outcome being Candida infection. We identified 3 distinct patient groups: 1) The Candida infection, 2) The Candida colonization and 3) the Candida-free group. All comparisons between groups with p-values ≤0.2 from the univariate analysis were entered into stepwise logistic regression to identify independent risk factors for candidiasis. RESULTS: 374 patients were included. Upon comparisons between groups, candidiasis patients received significantly more blood transfusions (p=0.013), antibiotics (p=0.005), and total parenteral nutrition (TPN) (p=0.004), had a longer duration of mechanical ventilation (MV) (p=0.008) and underwent more laparotomy procedures than Candida free patients (56.5% versus 16.4%; p<0.001). Surgical complications (13% versus 1.4%; p=0.013), injury of the upper (13% versus 0.9%; p=0.007) and lower gastrointestinal tract (8.7% versus 0.9%; p=0.048), and bacterial wound or intra-abdominal infections (17.4% versus 1.9%; p=0.004) were also more common in candidiasis patients. Upon multivariate analysis, patients receiving TPN had 7-fold higher odds for developing candidiasis (Odds ratio [OR]: 7.2; 95% Confidence interval [CI]: 2.6-19.4; p=0.0001). Other predisposing factors included laparotomy (OR: 3.8, 95% CI: 1.5-9.9; p=0.0057) and female gender (OR: 5.7; 95% CI: 2.1-15.6; p=0.0007). Average total hospital charges were higher for patients with Candida infection compared to patients with Candida colonization or without a positive Candida culture. CONCLUSIONS: TPN, laparotomy, and female gender independently predict the development of candidiasis among trauma patients. Severely injured women requiring laparotomy and TPN therapy should be carefully managed for the possibility of increased risk for candidiasis.
Asunto(s)
Candida/aislamiento & purificación , Candidiasis/epidemiología , Portador Sano/epidemiología , Heridas y Lesiones/complicaciones , Adulto , Anciano , Candidiasis/economía , Candidiasis/microbiología , Portador Sano/economía , Portador Sano/microbiología , Enfermedad Crítica , Femenino , Humanos , Laparotomía/efectos adversos , Masculino , Persona de Mediana Edad , Nutrición Parenteral/efectos adversos , Estudios Retrospectivos , Factores de Riesgo , Factores SexualesRESUMEN
BACKGROUND: The impact of reduced fluconazole susceptibility on clinical and economic outcomes in patients with Candida glabrata bloodstream infections (BSI) is unknown. METHODS: A retrospective cohort study was conducted to evaluate 30-day inpatient mortality and postculture hospital charges in patients with C glabrata BSI with decreased fluconazole susceptibility (minimum inhibitory concentration [MIC] ≥ 16 µg/mL) versus fluconazole-susceptible C glabrata BSI (MIC ≤ 8 µg/mL). These analyses were adjusted for demographics, comorbidities, and time at risk. Secondary analyses limited the C glabrata group with decreased fluconazole susceptibility to MIC ≥ 64 µg/mL. RESULTS: There were 45 (31%) deaths among 144 enrolled patients: 19 deaths (25%) among 76 patients with C glabrata BSI with decreased fluconazole susceptibility and 26 deaths (38%) among 68 patients with fluconazole-susceptible C glabrata BSI. Decreased fluconazole susceptibility was not independently associated with increased 30-day inpatient mortality (adjusted odds ratio, .60; 95% confidence interval (CI): .26-1.35; P = 0.22) or hospital charges (multiplicative change in hospital charges, .93; 95% CI: .60-1.43; P = 0.73). Older age was associated with increased mortality and increased time at risk was associated with increased hospital charges. CONCLUSION: Crude mortality rates remain high in patients with C glabrata BSI. However, decreased fluconazole susceptibility was not associated with increased mortality or hospital charges.
Asunto(s)
Antifúngicos/farmacología , Candida glabrata/efectos de los fármacos , Candidiasis/microbiología , Farmacorresistencia Fúngica , Fluconazol/farmacología , Fungemia/microbiología , Adulto , Anciano , Anciano de 80 o más Años , Candida glabrata/aislamiento & purificación , Candidiasis/tratamiento farmacológico , Candidiasis/economía , Candidiasis/mortalidad , Estudios de Cohortes , Femenino , Fungemia/tratamiento farmacológico , Fungemia/economía , Fungemia/mortalidad , Costos de la Atención en Salud , Humanos , Masculino , Pruebas de Sensibilidad Microbiana , Persona de Mediana Edad , Estudios Retrospectivos , Resultado del TratamientoRESUMEN
STUDY OBJECTIVES: To evaluate the impact of inappropriate therapy--defined as delayed antifungal therapy beyond 24 hours from culture collection, inadequate antifungal dosage, or administration of an antifungal to which an isolate was considered resistant--on postculture hospital length of stay and costs, and to evaluate the relationship between modifiable risk factors, including failure to remove a central venous catheter, antifungal delay, and inadequate dosage, for an additive effect on hospital length of stay and costs. DESIGN: Single-center retrospective cohort study. SETTING: 1250-bed academic medical center. PATIENTS: One hundred sixty-seven consecutive adult patients admitted between January 2004 and May 2006 with culture-confirmed Candida bloodstream infections that occurred within 14 days of hospital admission and who received at least one dose of antifungal treatment. MEASUREMENTS AND MAIN RESULTS: Patients were stratified according to appropriateness of antifungal therapy. Appropriate therapy was defined as initiation of an antifungal to which the isolated pathogen was sensitive in vitro within 24 hours of positive culture collection, in addition to receipt of an adequate dose as recommended by the Infectious Diseases Society of America and the antifungal package insert. Postculture length of stay was the primary outcome and hospital costs the secondary outcome. An evaluation of modifiable risk factors was performed separately. Data were analyzed for 167 patients (22 in the appropriate therapy group and 145 in the inappropriate therapy group). Postculture length of stay was shorter in the appropriate therapy group (mean 7 vs 10.4 days, p=0.037). This correlated with total hospital costs that were lower in the appropriate therapy group (mean $15,832 vs $33,021, p<0.001.) A graded increase in costs was noted with increasing number of modifiable risk factors (p=0.001). CONCLUSION: Inappropriate therapy for Candida bloodstream infection occurring within 14 days of hospitalization was associated with prolonged postculture length of stay and increased costs. A rise in costs, but not length of stay, was noted with increasing modifiable risk factors.
Asunto(s)
Antifúngicos/uso terapéutico , Candida/efectos de los fármacos , Candidiasis/tratamiento farmacológico , Cateterismo Venoso Central/efectos adversos , Hospitalización/economía , Adulto , Antifúngicos/economía , Candidiasis/economía , Candidiasis/etiología , Cateterismo Venoso Central/economía , Estudios de Cohortes , Costos y Análisis de Costo/economía , Costos de Hospital , Humanos , Estudios Retrospectivos , Factores de RiesgoRESUMEN
We compared costs, length of stay, and mortality between adults with Candida albicans and Candida glabrata bloodstream infections. Early evidence of C glabrata, as defined by a positive culture within 2 days of admission, was associated with higher costs ($56,026 vs $32,810; P = .04) and longer hospital stays (19.7 vs 14.5 days; P = .05) compared with early evidence of C albicans. Mortality was similar between the groups.
Asunto(s)
Candida albicans/aislamiento & purificación , Candida glabrata/aislamiento & purificación , Candidiasis/economía , Candidiasis/mortalidad , Fungemia/economía , Fungemia/mortalidad , Tiempo de Internación/estadística & datos numéricos , Adulto , Anciano , Anciano de 80 o más Años , Candidiasis/microbiología , Candidiasis/patología , Infección Hospitalaria/economía , Infección Hospitalaria/microbiología , Infección Hospitalaria/mortalidad , Infección Hospitalaria/patología , Femenino , Fungemia/microbiología , Fungemia/patología , Humanos , Masculino , Persona de Mediana Edad , Adulto JovenRESUMEN
BACKGROUND: There were 1967 reports of Candida species isolated from blood specimens in 2007 in the UK (excluding Scotland). Such infections are particularly common in the intensive care unit (ICU). The impact of candidaemia on mortality, length of stay (LOS) and cost in a UK hospital was examined. METHODS: A retrospective analysis of candidaemia episodes and appropriate matched controls was undertaken based on data from the ICU, high dependency units and hospital wards at Wythenshawe Hospital in Manchester. The study covered the period November 2003-February 2007. RESULTS: In total, 48 case-patients of candidaemia and 81 control-patients were identified. The attributable mortality due to candidaemia varied from 21.5% to 34.7%. Candidaemia patients spend on average 5.6 days more in the ICU than matched patients and generate mean additional costs of at least 8252 UK pounds per patient, 16,595 pounds in adults only. CONCLUSION: Candidaemia remains a severe disease associated with high attributable mortality in the UK. In addition, candidaemia leads to additional ICU length of stay and costs. The implication is an attributable cost of at least 16.2 million UK pounds with 683 deaths attributable to candidaemia per year in the UK.
Asunto(s)
Candidiasis/economía , Candidiasis/mortalidad , Fungemia/economía , Fungemia/mortalidad , Tiempo de Internación/estadística & datos numéricos , Adolescente , Adulto , Anciano , Candida albicans/aislamiento & purificación , Niño , Preescolar , Femenino , Humanos , Lactante , Recién Nacido , Unidades de Cuidados Intensivos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Reino Unido , Adulto JovenRESUMEN
BACKGROUND: Invasive candidiasis episodes have increased during last years and they have been related with high rates of crude mortality. Invasive candidiasis-related deaths have not diminished significantly with the introduction of antifungals in the past decade. Finantial managers are worried about extra costs from acquisition of new antifungal agents. AIM: This review includes the main studies age-stratified to assess different variables related to the economic burden of invasive candidiasis. METHODS: Systematic review of biomedic databases including Medline, PubMed and EMBASE. RESULTS: The studies show hospital stay as the main variable related with higher impact in the increase of invasive candidiasis costs. Acquisition costs of antifungals have a very low impact in the invasive candidiasis costs. CONCLUSIONS: Pharmacoeconomics applied in candidiasis invasive therapy must avoid assessing acquisition costs of antifungals exclusively, needing to include both direct and indirect costs associated with this fungal infection. The cost of antifungal acquisition represents a low impact in the overall economic burden of this fungal infection. Further pharmacoeconomics evaluations should be performed including similar definitions to decrease the possible bias in results interpretation.
Asunto(s)
Antifúngicos/economía , Candidiasis/tratamiento farmacológico , Fungemia/tratamiento farmacológico , Adulto , Factores de Edad , Antifúngicos/uso terapéutico , Candidiasis/economía , Niño , Infección Hospitalaria/tratamiento farmacológico , Infección Hospitalaria/economía , Costos de los Medicamentos , Financiación Gubernamental/estadística & datos numéricos , Financiación Personal/estadística & datos numéricos , Fungemia/economía , Costos de Hospital , Hospitalización/economía , Humanos , Recién Nacido de Bajo Peso , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/tratamiento farmacológico , Enfermedades del Prematuro/economía , Tiempo de Internación/economía , Estudios Prospectivos , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Infecciones Relacionadas con Prótesis/economía , Estudios RetrospectivosRESUMEN
We compared length of stay, inpatient costs, and mortality associated with Candida albicans and non-albicans bloodstream infections in adults and children. Compared with adults, children with Candida bloodstream infections had longer lengths of stay (36.7 vs. 20.7 days; P < 0.001) and higher inpatient costs ($133,871 vs. $56,725; P < 0.001) but lower mortality (28.3% vs. 43.5%; P < 0.001).
Asunto(s)
Candida/aislamiento & purificación , Candidiasis/microbiología , Candidiasis/mortalidad , Fungemia/microbiología , Fungemia/mortalidad , Adolescente , Adulto , Candidiasis/economía , Niño , Preescolar , Estudios de Cohortes , Fungemia/economía , Costos de la Atención en Salud , Hospitalización/economía , Humanos , Lactante , Tiempo de Internación/economía , Adulto JovenRESUMEN
Antecedentes: Con los años, los episodios de candidiasis invasora se han incrementado y se han asociado con ratios elevados de mortalidad bruta. Los antifúngicos introducidos durante la pasada década no han producido una disminución significativa de la mortalidad relacionada con esta enfermedad infecciosa. Los costes de adquisición de los antifúngicos suponen una gran preocupación en la gestión de los costes de farmacia. Objetivos: Desarrollar una revisión de los principales estudios efectuados, estratificados por grupos de edad, para evaluar las distintas variables que afectan a la carga económica, así como los costes ocasionados por la candidiasis invasora. Métodos: Búsqueda sistemática de bases de datos Medline, PubMed y EMBASE. Resultados: Los estudios efectuados en pacientes con candidiasis invasora muestran que la estancia hospitalaria es la variable con más impacto en el incremento de los costes relacionados con esta infección fúngica. El coste de adquisición de los antifúngicos representa un porcentaje muy inferior al de otras variables analizadas. Conclusiones: El análisis farmacoeconómico de la candidiasis invasora requiere la inclusión del estudio de los costes directos e indirectos que lleva asociados, y no tan sólo, el de los costes de adquisición de los antifúngicos. Estos últimos representan una pequeña parte del coste total de esta enfermedad. Es preciso efectuar nuevos análisis farmacoeconómicos que unifiquen las definiciones utilizadas en los estudios con el fin de disminuir su impacto en la interpretación de los resultados (AU)
Background: Invasive candidiasis episodes have increased during last years and they have been related with high rates of crude mortality. Invasive candidiasis-related deaths have not diminished significantly with the introduction of antifungals in the past decade. Finantial managers are worried about extra costs from acquisition of new antifungal agents. Aim: This review includes the main studies agestratified to assess different variables related to the economic burden of invasive candidiasis. Methods: Systematic review of biomedic databases including Medline, PubMed and EMBASE. Results: The studies show hospital stay as the main variable related with higher impact in the increase of invasive candidiasis costs. Acquisition costs of antifungals have a very low impact in the invasive candidiasis costs. Conclusions: Pharmacoeconomics applied in candidiasis invasive therapy must avoid assessing acquisition costs of antifungals exclusively, needing to include both direct and indirect costs associated with this fungal infection. The cost of antifungal acquisition represents a low impact in the overall economic burden of this fungal infection. Further pharmacoeconomics evaluations should be performed including similar definitions to decrease the possible bias in results interpretation (AU)
Asunto(s)
Humanos , Recién Nacido , Adulto , Antifúngicos/economía , Candidiasis/tratamiento farmacológico , Fungemia/tratamiento farmacológico , Fungemia/economía , Infecciones Relacionadas con Prótesis/tratamiento farmacológico , Infecciones Relacionadas con Prótesis/economía , Recien Nacido Prematuro , Enfermedades del Prematuro/tratamiento farmacológico , Enfermedades del Prematuro/economía , Recién Nacido de Bajo Peso , Factores de Edad , Antifúngicos/uso terapéutico , Candidiasis/economía , Costos de los Medicamentos , Financiación Gubernamental/estadística & datos numéricos , Financiación Personal/estadística & datos numéricos , Costos de Hospital , Hospitalización/economía , Estudios Retrospectivos , Estudios Prospectivos , Tiempo de Internación/economíaRESUMEN
Candida bloodstream infection (CBSI) accounted for 50% of bloodstream infections in our medical intensive care unit (MICU) in 2004. Our objective was to evaluate a risk-based fluconazole prophylaxis program. CBSI incidence, patient demographics, and unit metrics were retrospectively reviewed for 2004. Starting on January 2005, patients meeting pre-specified criteria were placed on risk-based fluconazole prophylaxis and their outcomes, adverse events, and unit metrics were prospectively collected. The inclusion criteria were based on a clinical prediction rule and included an MICU stay greater than 72 h, broad-spectrum antibiotics, and central venous catheter, along with at least two of the following: mechanical ventilation for at least 48 h, any type of dialysis, parenteral nutrition, pancreatitis, systemic steroids, or other systemic immunosuppressive agents. For 2004, the unit had nine CBSI, corresponding to a rate of 3.4 CBSI/1,000 line-days. Four cases were caused by C. albicans, four by C. glabrata, and one by C. tropicalis. The mean +/- standard deviation (SD) APACHE II score for these patients was 25 +/- 9. In 2005, a total of 36 patients (2.6% of all unit admissions) received prophylaxis and the unit had two CBSI, corresponding to a rate of 0.79 CBSI/1,000 line-days. One patient had C. albicans and the other had C. tropicalis. The mean +/- SD APACHE II score for these patients was 21 +/- 8. The mean +/- SD duration of fluconazole prophylaxis was 8 +/- 6 days. Fluconazole was discontinued in two patients due to non-severe adverse events (acute eosinophilia, elevated transaminases). The attributable cost of CBSI in the unit in 2004 was $63,000 per episode. The total cost for the 36 courses of fluconazole was $6,000. When comparing the 2004 CBSI patients and the 2005 prophylaxis patients, we found similar acuity, demographics, and risk factors, with no differences in MICU or hospital mortality or length of stay. Risk-based fluconazole prophylaxis in an MICU with a high incidence of CBSI was safe and cost-effective when applied to a limited number of patients and produced a significant decrease in the incidence of this disease.
Asunto(s)
Antifúngicos/uso terapéutico , Candidiasis/prevención & control , Quimioprevención/métodos , Diálisis/efectos adversos , Fluconazol/uso terapéutico , Fungemia/prevención & control , Adulto , Animales , Antifúngicos/efectos adversos , Candidiasis/economía , Fluconazol/efectos adversos , Fungemia/economía , Costos de la Atención en Salud , Humanos , Unidades de Cuidados Intensivos , Persona de Mediana Edad , Resultado del TratamientoRESUMEN
OBJECTIVE: Assess the impact of esophageal candidiasis on US hospital inpatient charges, length of stay (LOS), and costs across clinically relevant subgroups. METHODS: Total hospital charge (THC) and LOS data extracted from the 2005 National Inpatient Sample (NIS) were compared for patients with and without esophageal candidiasis within the top 20 most commonly assigned Diagnosis Related Groups (DRGs) for the disease. Total hospital costs were estimated using hospital charges in the 2005 Medicare Provider Analysis and Review (MEDPAR) file and hospital cost-to-charge ratios published in the Center for Medicare and Medicaid Service's (CMS) 2005 Inpatient Prospective Payment System Standardization File. RESULTS: Across 274 DRGs, 45 727 esophageal candidiasis patients were identified. Mean age was 50.8 years; 52.5% were female, 59.3% Caucasian. Median LOS was 7 days; median THC was $25 649. Of all esophageal candidiasis cases identified, 65% fell into the top 20 most commonly assigned DRGs. Within this subset, HIV-related DRGs accounted for 22% of the esophageal candidiasis cases. The difference in mean THC and LOS for esophageal candidiasis patients in HIV-related DRGs was not significant. However, total hospital costs were higher for esophageal candidiasis patients in this subset ($11 886 vs. $10 534, p < 0.01). The remaining 78% of esophageal candidiasis cases were assigned to 19 non-HIV-related DRGs. Mean LOS, THC, and total hospital costs were significantly higher for esophageal candidiasis patients within these 19 non-HIV-related DRGs, (8.4 vs. 6.1; $35 704 vs. $23 874, and $10 917 vs. $7474, p < 0.01 in all cases). CONCLUSIONS: Esophageal candidiasis affects a wide range of patient groups; it increases LOS and total charges within non-HIV-related hospitalizations. Although the costs presented in this study are estimates, they do suggest a significant increase in cost among esophageal candidiasis cases. Future studies on treatment and preventive care strategies for esophageal candidiasis should not be limited to HIV patients, but instead performed across a wider range of disease settings.